Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down – Here’s What Happened

Telix Pharmaceuticals Limited (NASDAQ:TLX)’s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $12.83, but opened at $12.22. Telix Pharmaceuticals shares last traded at $11.7050, with a volume of 138,711 shares.

Wall Street Analyst Weigh In

TLX has been the topic of a number of analyst reports. Citigroup reiterated a “buy” rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. Weiss Ratings upgraded Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, August 21st. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a report on Tuesday. Wedbush reissued an “outperform” rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a research report on Monday. Finally, Royal Bank Of Canada downgraded Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Telix Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $20.40.

Telix Pharmaceuticals Stock Up 5.7%

The company has a quick ratio of 1.85, a current ratio of 2.01 and a debt-to-equity ratio of 1.16. The stock has a 50 day simple moving average of $11.27 and a 200-day simple moving average of $10.31.

Institutional Trading of Telix Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Lazard Asset Management LLC increased its holdings in shares of Telix Pharmaceuticals by 15.7% in the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after purchasing an additional 39,400 shares during the last quarter. Private Advisor Group LLC boosted its stake in Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after buying an additional 128,070 shares during the last quarter. Hennion & Walsh Asset Management Inc. bought a new position in shares of Telix Pharmaceuticals during the 2nd quarter valued at approximately $1,731,000. XY Capital Ltd lifted its position in Telix Pharmaceuticals by 468.0% during the second quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock valued at $822,000 after purchasing an additional 58,739 shares during the last quarter. Finally, Bank of America Corp DE grew its position in Telix Pharmaceuticals by 523.8% in the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after acquiring an additional 8,423 shares in the last quarter.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.